[go: up one dir, main page]

ES2115725T3 - TRIAZOLYLTIOMETHYLETHEOPHALOSPORINE HYDROCHLORIDE, ITS CRYSTALLINE HYDRATE AND THE PREPARATION OF IT. - Google Patents

TRIAZOLYLTIOMETHYLETHEOPHALOSPORINE HYDROCHLORIDE, ITS CRYSTALLINE HYDRATE AND THE PREPARATION OF IT.

Info

Publication number
ES2115725T3
ES2115725T3 ES93305864T ES93305864T ES2115725T3 ES 2115725 T3 ES2115725 T3 ES 2115725T3 ES 93305864 T ES93305864 T ES 93305864T ES 93305864 T ES93305864 T ES 93305864T ES 2115725 T3 ES2115725 T3 ES 2115725T3
Authority
ES
Spain
Prior art keywords
hydrochloride
triazolyltiomethyletheophalosporine
preparation
crystalline hydrate
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93305864T
Other languages
Spanish (es)
Inventor
Hisanori Takahashi
Yutaka Ide
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of ES2115725T3 publication Critical patent/ES2115725T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PRESENTAN HIDROCLORURO DE ACIDO 7(BETA)-[(Z)-2-(2-AMINO 4 TIAZOLIL)2-HIDROXIIMINOACETAMIDO]-3-(1,2,3-TRIAZOL-4-IL)TIOMETILTIO-3-CEFEM-4CARBOXILICO Y SUS HIDRATOS CRISTALINOS, QUE TIENEN UNA POTENTE ACTIVIDAD ANTIBIOTICA Y SON DE BAJA TOXICIDAD Y FARMACOLOGICAMENTE ESTABLES, SIENDO UTILES POR LO TANTO COMO INGREDIENTES ACTIVOS DE PRODUCTOS CLINICOS UTILES EN FORMULACIONES ANTIBIOTICAS, ASIMISMO SE PRESENTA UN PROCESO PARA LA PRODUCCION DE LOS MISMOS.ACID HYDROCHLORIDE 7 (BETA) - [(Z) -2- (2-AMINO 4 THIAZOLYL) 2-HYDROXYIMINOACETAMIDO] -3- (1,2,3-TRIAZOL-4-IL) THYOMETHYL-3-CEFEM- ARE PRESENT 4CARBOXYLIC AND ITS CRYSTALLINE HYDRATES, WHICH HAVE A POWERFUL ANTIBIOTIC ACTIVITY AND ARE LOW TOXICITY AND PHARMACOLOGICALLY STABLE, BEING USEFUL AS AN ACTIVE INGREDIENTS OF USEFUL CLINICAL PRODUCTS IN SETIMATE ANTIBIOTIC PRODUCTS.

ES93305864T 1992-07-31 1993-07-26 TRIAZOLYLTIOMETHYLETHEOPHALOSPORINE HYDROCHLORIDE, ITS CRYSTALLINE HYDRATE AND THE PREPARATION OF IT. Expired - Lifetime ES2115725T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31

Publications (1)

Publication Number Publication Date
ES2115725T3 true ES2115725T3 (en) 1998-07-01

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93305864T Expired - Lifetime ES2115725T3 (en) 1992-07-31 1993-07-26 TRIAZOLYLTIOMETHYLETHEOPHALOSPORINE HYDROCHLORIDE, ITS CRYSTALLINE HYDRATE AND THE PREPARATION OF IT.

Country Status (23)

Country Link
US (1) US5407929A (en)
EP (1) EP0581552B1 (en)
KR (1) KR100245938B1 (en)
CN (1) CN1037683C (en)
AT (1) ATE165360T1 (en)
AU (1) AU657866B2 (en)
BR (1) BR9303235A (en)
CA (1) CA2101502A1 (en)
DE (1) DE69318077T2 (en)
ES (1) ES2115725T3 (en)
FI (1) FI933391L (en)
GR (1) GR3026699T3 (en)
HU (1) HU219637B (en)
IL (1) IL106516A (en)
MX (1) MX9304611A (en)
NO (1) NO303734B1 (en)
NZ (1) NZ248285A (en)
PH (1) PH30109A (en)
PL (2) PL172830B1 (en)
RU (1) RU2118959C1 (en)
TW (1) TW307769B (en)
UA (1) UA37181C2 (en)
ZA (1) ZA935529B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286975B6 (en) * 2001-02-24 2009-08-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use
AT413282B (en) * 2002-02-01 2006-01-15 Sandoz Ag CRYSTALLINE SALTS OF 7 - (((5-AMINO-1,2,4-THIADIAZOL-3-YL) (FLUOROMETHOXY-IMINO) ACETYL) AMINO) -3- ((IMINO-1-PIPERAZINYLMETHYL)
KR20030076759A (en) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 Novel cephalosporin compounds and process for preparing same
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
EP3299359A1 (en) 2003-02-12 2018-03-28 Nissan Chemical Industries, Ltd. Crystalline and amorphous forms of pitavastatin hemicalcium salt
PT1606293E (en) 2003-03-27 2009-10-14 Basilea Pharmaceutica Ag Cephalosporin in crystalline form
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
BRPI0711558A2 (en) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polymorphs
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2696579C (en) * 2007-08-17 2017-01-24 Boehringer Ingelheim International Gmbh Purine derivatives for use in the treatment of fab-related diseases
PE20091730A1 (en) 2008-04-03 2009-12-10 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
PE20100156A1 (en) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int NAFLD TREATMENT
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
NZ604091A (en) * 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
BRPI0919288A2 (en) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh combination therapy for treatment of diabetes and related conditions.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
PH12012501037A1 (en) 2009-11-27 2013-01-14 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
KR20230051307A (en) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
ES2713566T3 (en) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivative of substituted dinamic quinazoline, its preparation and its use in pharmaceutical compositions for the treatment of type I and II diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (en) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co A procedure to prepare new compounds of cefem (Machine-translation by Google Translate, not legally binding)
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
UA37181C2 (en) 2001-05-15
NO303734B1 (en) 1998-08-24
EP0581552A2 (en) 1994-02-02
PL172835B1 (en) 1997-12-31
PH30109A (en) 1996-12-27
FI933391A7 (en) 1994-02-01
BR9303235A (en) 1994-03-01
NO932745L (en) 1994-02-01
CN1037683C (en) 1998-03-11
EP0581552A3 (en) 1994-06-01
HU219637B (en) 2001-06-28
ZA935529B (en) 1994-02-24
RU2118959C1 (en) 1998-09-20
KR940005636A (en) 1994-03-22
AU657866B2 (en) 1995-03-23
HU9302194D0 (en) 1993-10-28
DE69318077T2 (en) 1998-10-29
IL106516A (en) 1998-06-15
FI933391L (en) 1994-02-01
DE69318077D1 (en) 1998-05-28
NO932745D0 (en) 1993-07-30
KR100245938B1 (en) 2000-04-01
CN1089948A (en) 1994-07-27
PL299870A1 (en) 1994-02-07
GR3026699T3 (en) 1998-07-31
CA2101502A1 (en) 1994-02-01
FI933391A0 (en) 1993-07-29
AU4422793A (en) 1994-02-03
PL172830B1 (en) 1997-12-31
IL106516A0 (en) 1993-11-15
EP0581552B1 (en) 1998-04-22
HUT68602A (en) 1995-06-28
ATE165360T1 (en) 1998-05-15
US5407929A (en) 1995-04-18
TW307769B (en) 1997-06-11
NZ248285A (en) 1994-07-26
MX9304611A (en) 1994-02-28

Similar Documents

Publication Publication Date Title
ES2115725T3 (en) TRIAZOLYLTIOMETHYLETHEOPHALOSPORINE HYDROCHLORIDE, ITS CRYSTALLINE HYDRATE AND THE PREPARATION OF IT.
PT750618E (en) OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
ATE61050T1 (en) PYRIDAZINAMINES EFFECTIVE AGAINST VIRUSES.
ECSP941104A (en) DERIVATIVES OF 2,6 DIAMINOPURINE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
PT91108A (en) A process for the preparation of a pharmaceutical composition comprising an active ingredient such as a colic acid salt and an inhibitor product for activating the absorption of the active ingredient by the human body
AR019853A1 (en) DERIVED FROM THE 3-ARIL-2-HYDROXIPROPIONIC ACID, PROCESS AND INTERMEDIARY FOR THEIR PREPARATION, PHARMACEUTICAL FORMULATIONS, USE OF SUCH COMPOUND IN THE PREPARATION OF A MEDICINAL PRODUCT, METHOD FOR THE PROPHYLAXIS AND / OR TREATMENT OF CLINIC ASSOCIATED RESISTANCES AND FORMULATION
FI960032L (en) Pharmaceutical compositions for poorly soluble active ingredients
BG60102B2 (en) Method for preparing of 5-fluoro-2[[(4-cyclopropylmethoxy-2-pyridyl)methyl]thionyl]-1h-ben zimidazole
ES2129485T3 (en) DERIVATIVES OF GUANIDINOALKYL-1,1-BISPHOSPHONIC ACIDS, PROCEDURE FOR THEIR PREPARATION AND USE.
ES2063146T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING N- (3,4-DIMETOXICINAMOIL) -ANTRANILICO ACID.
ES2093440T3 (en) DERIVATIVES IN THE SERIES OF VITAMIN D WITH MODIFICATIONS IN POSITION 20, PROCEDURE FOR ITS PREPARATION, INTERMEDIATE PRODUCTS FOR THIS PROCEDURE, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES.
BR9812492A (en) Compound, use of it, pharmaceutical formulation, and processes for the treatment of cardiovascular disease, for the treatment of vasoconstriction, and for the preparation of compounds
ES2134801T3 (en) CRYSTAL TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE.
KR920701213A (en) Methylenediphosphonic acid compound and anti-inflammatory agent using it as an active ingredient
ES2134237T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING URSODESOXICOLICO ACID.
AR012946A1 (en) CRYSTALLINE A FORM OF 1- (2,6-DIFLUORBENCIL) -1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE FOR THE PREPARATION OF MEDICINES
ES2111352T3 (en) USE OF DIESTER PHOSPHATE FOR THE TREATMENT OF RETINAL DISEASES.
ATE151636T1 (en) MEDICINAL PRODUCTS CONTAINING DIPHOSPHONIC ACIDS AND THEIR SALTS
PT91203A (en) PROCESS FOR THE PREPARATION OF NEW DERIVATIVES OF BU-3608 ANTIBIOTICS AND OF PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
BR9611276A (en) Compound pharmaceutical formulation process for treatment or prophylaxis of diseases or conditions of humans and use of a compound
ES2072386T3 (en) DERIVATIVES OF PENCICLOVIR FOR THE TREATMENT OF HEPATITIS-B INFECTIONS.
DK429480A (en) PHOSPHONO HYDROXYDIC ACETIC ACID PROCEDURES FOR PREPARING IT AND USING IT AS A MEDICINE
ES2043943T3 (en) PROCEDURE FOR THE PREPARATION OF COMPOUNDS WITH CENTRAL ANALGESIC ACTIVITY.
MX9305523A (en) IMPROVED CHEMOTHERAPEUTIC COMPOSITIONS AGAINST MICROBIAL INFECTIONS IN FISH, THE REPAIR AND USE OF THE SAME.
MX9303574A (en) HETERO-CYCLE COMPOUNDS THAT ARE INHIBITORS OF THE AROMATASE ENZYME, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 581552

Country of ref document: ES